```
 e cediranib/cn
E1            1     CEDIN/CN
E2            1     CEDINOL/CN
E3            1 --> CEDIRANIB/CN
E4            1     CEDIRANIB MALEATE/CN
E5            1     CEDKATHRYN A/CN
E6            1     CEDKATHRYN B/CN
E7            1     CEDMILIN/CN
E8            1     CEDMILINE/CN
E9            1     CEDMILINOL/CN
E10           1     CEDO 8811/CN
E11           1     CEDO 8816/CN
E12           1     CEDO 8834/CN

=> s e3
L1            1 CEDIRANIB/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   288383-20-0  REGISTRY
ED   Entered STN:  08 Sep 2000
CN   Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-
     pyrrolidinyl)propoxy]-  (CA INDEX NAME)
OTHER NAMES:
CN   4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-
     yl)propoxy]quinazoline
CN   4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-
     yl)propoxy]quinazoline
CN   AZD 2171
CN   Cediranib
CN   ZD 2171
DR   790713-41-6, 557795-03-6
MF   C25 H27 F N4 O3
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, EMBASE,
       IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, PROUSDDR, RTECS*, SYNTHLINE,
       TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
             100 REFERENCES IN FILE CA (1907 TO DATE)
               6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             104 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus
> file reg

=> e irinotecan/cn
E1           1     IRINITE/CN
E2           1     IRINOPHORE C/CN
E3           1 --> IRINOTECAN/CN
E4           1     IRINOTECAN HYDROCHLORIDE/CN
E5           1     IRINOTECAN HYDROCHLORIDE HYDRATE/CN
E6           1     IRINOTECAN HYDROCHLORIDE SESQUIHYDRATE/CN
E7           1     IRINOTECAN HYDROCHLORIDE TRIHYDRATE/CN
E8           1     IRINOTECAN LACTONE/CN
E9           1     IRINOTECAN-TETRAZOLIUM VIOLET MIXT./CN
E10          1     IRINOTECAN-VINCRISTINE N-OXIDE MIXT./CN
E11          1     IRIOBRONZE FINE SILVER/CN
E12          1     IRIODIN/CN

=> s e3
L2           1 IRINOTECAN/CN

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   97682-44-5  REGISTRY
ED   Entered STN:  18 Aug 1985
CN   [1,4'-Bipiperidine]-1'-carboxylic acid,
     (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-
     pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline,
     [1,4'-bipiperidine]-1'-carboxylic acid deriv.
CN   [1,4'-Bipiperidine]-1'-carboxylic acid,
     4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-
     pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, (S)-
OTHER NAMES:
CN   (+)-Irinotecan
CN   Irinophore C
CN   Irinotecan
CN   Irinotecan lactone
FS   STEREOSEARCH
MF   C33 H38 N4 O6
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
       HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE,
       MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
       USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.  Rotation (+).
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3414 REFERENCES IN FILE CA (1907 TO DATE)
72 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3431 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e 5-fluorouracil/cn
E1            1     5-FLUOROTRYPTOPHOL/CN
E2            1     5-FLUOROTUBERCIDIN/CN
E3            1 --> 5-FLUOROURACIL/CN
E4            1     5-FLUOROURACIL 2'-DEOXYRIBOSIDE/CN
E5            1     5-FLUOROURACIL ARABINONUCLEOSIDE 5'-PHOSPHATE/CN
E6            1     5-FLUOROURACIL DEOXYRIBONUCLEOSIDE 5'-PHOSPHATE/CN
E7            1     5-FLUOROURACIL DEOXYRIBOSIDE/CN
E8            1     5-FLUOROURACIL ION(1-)/CN
E9            1     5-FLUOROURACIL LITHIUM SALT/CN
E10           1     5-FLUOROURACIL MONOSODIUM SALT/CN
E11           1     5-FLUOROURACIL NITRATE/CN
E12           1     5-FLUOROURACIL PHOSPHORIBOSYLTRANSFERASE/CN

=> s e3
L3            1 5-FLUOROURACIL/CN

=> d

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   51-21-8  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   2,4(1H,3H)-Pyrimidinedione, 5-fluoro-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Uracil, 5-fluoro- (8CI)
OTHER NAMES:
CN   2,4-Dihydroxy-5-fluoropyrimidine
CN   2,4-Dioxo-5-fluoropyrimidine
CN   5-Fluoracyl
CN   5-Fluoro-2,4(1H,3H)-pyrimidinedione
```

CN 5-Fluoro-2,4-pyrimidinedione
CN 5-Fluoropyrimidine-2,4-diol
CN 5-Fluorouracil
CN 5-FU
CN Adrucil
CN Arumel
CN Carac
CN Carzonal
CN Efudex
CN Efudix
CN Efurix
CN Fluoroblastin
CN Fluoroplex
CN Fluorouracil
CN Flurablastin
CN Fluracedyl
CN Fluracil
CN Fluracilum
CN Fluri
CN Fluril
CN Ftoruracil
CN FU
CN Kecimeton
CN NSC 19893
CN Phthoruracil
CN Phtoruracil
CN Queroplex
CN Ro 2-9757
CN Timazin
CN U 8953
CN Ulup
DR 1004-03-1, 79108-01-3, 4921-97-5
MF C4 H3 F N2 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD, VETU
      (*File contains numerically searchable property data)
    Other Sources: EINECS**, NDSL**, TSCA**, WHO
      (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
           21449 REFERENCES IN FILE CA (1907 TO DATE)
             500 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
           21546 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus

=> d his

     (FILE 'HOME' ENTERED AT 17:49:55 ON 22 OCT 2009)

     FILE 'REGISTRY' ENTERED AT 17:50:43 ON 22 OCT 2009
                E CEDIRANIB/CN
L1            1 S E3

     FILE 'CAPLUS' ENTERED AT 17:51:19 ON 22 OCT 2009

     FILE 'REGISTRY' ENTERED AT 17:51:28 ON 22 OCT 2009
                E IRINOTECAN/CN
L2            1 S E3
                E 5-FLUOROURACIL/CN
L3            1 S E3

     FILE 'CAPLUS' ENTERED AT 17:52:26 ON 22 OCT 2009

=> s l1 (L) (l2 or l3)
           104 L1
          3431 L2
         21546 L3
L4           0 L1 (L) (L2 OR L3)

=> s l1 and (l2 or l3)
           104 L1
          3431 L2
         21546 L3
L5          26 L1 AND (L2 OR L3)

=> s l5 and py<2005
      25144356 PY<2005
L6           1 L5 AND PY<2005

=> d ibib abs hitind

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2004:965067  CAPLUS <<LOGINID::20091022>>
DOCUMENT NUMBER:         141:406039
TITLE:                   Combinations for the treatment of diseases involving
                         cell proliferation, migration or apoptosis of myeloma
                         cells, or angiogenesis
INVENTOR(S):             Hilberg, Frank; Solca, Flavio; Stefanic, Martin
                         Friedrich; Baum, Anke; Munzert, Gerd; Van Meel,
                         Jacobus C. A.
PATENT ASSIGNEE(S):      Boehringer Ingelheim International G.m.b.H., Germany;
                         Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE:                  PCT Int. Appl., 101 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424 <--
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424 <--
CA 2523868	A1	20041111	CA 2004-2523868	20040424 <--
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
IN 2005DN04018	A	20091002	IN 2005-DN4018	20050907
MX 2005011656	A	20051215	MX 2005-11656	20051028
NO 2005005605	A	20051128	NO 2005-5605	20051128
PRIORITY APPLN. INFO.:			EP 2003-9587 A	20030429
			EP 2004-508 A	20040113
			EP 2004-1171 A	20040121
			WO 2004-EP4363 W	20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IC ICM A61K031-496

=> d his

(FILE 'HOME' ENTERED AT 17:49:55 ON 22 OCT 2009)

FILE 'REGISTRY' ENTERED AT 17:50:43 ON 22 OCT 2009
E CEDIRANIB/CN
L1 1 S E3

FILE 'CAPLUS' ENTERED AT 17:51:19 ON 22 OCT 2009

FILE 'REGISTRY' ENTERED AT 17:51:28 ON 22 OCT 2009
E IRINOTECAN/CN

```
L2            1 S E3
                E 5-FLUOROURACIL/CN
L3            1 S E3

     FILE 'CAPLUS' ENTERED AT 17:52:26 ON 22 OCT 2009
L4            0 S L1 (L) (L2 OR L3)
L5           26 S L1 AND (L2 OR L3)
L6            1 S L5 AND PY<2005

=> s l5 and py=2005
       1432022 PY=2005
L7            3 L5 AND PY=2005

=> d ibib 1-3

L7   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2005:1075607  CAPLUS <<LOGINID::20091022>>
DOCUMENT NUMBER:          143:339615
TITLE:                    AZD2171 in combination with 5-FU and/or CPT-11 for the
                          treatment of cancer
INVENTOR(S):              Wedge, Stephen Robert
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE:                   PCT Int. Appl., 47 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005092303         A2    20051006    WO 2005-GB1080          20050322 <--
     WO 2005092303         A3    20061102
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     AU 2005225193         A1    20051006    AU 2005-225193          20050322 <--
     AU 2005225193         B2    20081009
     CA 2610628            A1    20051006    CA 2005-2610628         20050322 <--
     EP 1729808            A2    20061213    EP 2005-729381          20050322
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
             HR, LV, MK, YU
     CN 1964742            A     20070516    CN 2005-80009218        20050322
     BR 2005008982         A     20070828    BR 2005-8982            20050322
     JP 2007530518         T     20071101    JP 2007-504467          20050322
     ZA 2006007555         A     20080528    ZA 2006-7555            20060908
     MX 2006010758         A     20061215    MX 2006-10758           20060920
     US 20080125447        A1    20080529    US 2006-594233          20060925
     NO 2006004755         A     20061020    NO 2006-4755            20061020
     KR 2006130763         A     20061219    KR 2006-721774          20061020
```

PRIORITY APPLN. INFO.: GB 2004-6446 A 20040323
WO 2005-GB1080 W 20050322
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:99470 CAPLUS <<LOGINID::20091022>>
DOCUMENT NUMBER: 142:197889
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009961	A2	20050203	WO 2004-US23500	20040722 <--
WO 2005009961	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259760	A1	20050203	AU 2004-259760	20040722 <--
CA 2532865	A1	20050203	CA 2004-2532865	20040722 <--
US 20050038080	A1	20050217	US 2004-895985	20040722 <--
EP 1663978	A2	20060607	EP 2004-786091	20040722
EP 1663978	B1	20071128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004012219	A	20060822	BR 2004-12219	20040722
CN 1856469	A	20061101	CN 2004-80021091	20040722
JP 2006528196	T	20061214	JP 2006-521221	20040722
ES 2297490	T3	20080501	ES 2004-786091	20040722
ZA 2006000609	A	20070530	ZA 2006-609	20060120
KR 2006052866	A	20060519	KR 2006-701558	20060123
MX 2006000860	A	20060720	MX 2006-860	20060123
IN 2006DN00402	A	20070824	IN 2006-DN402	20060123
NO 2006000870	A	20060407	NO 2006-870	20060222

PRIORITY APPLN. INFO.: US 2003-489102P P 20030723
US 2004-540326P P 20040202
WO 2004-US23500 W 20040722
OTHER SOURCE(S): CASREACT 142:197889
OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965067 CAPLUS <<LOGINID::20091022>>
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	A1	20041111	CA 2004-2523868	20040424
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
IN 2005DN04018	A	20091002	IN 2005-DN4018	20050907
MX 2005011656	A	20051215	MX 2005-11656	20051028 <--
NO 2005005605	A	20051128	NO 2005-5605	20051128 <--

PRIORITY APPLN. INFO.:

EP 2003-9587	A	20030429
EP 2004-508	A	20040113
EP 2004-1171	A	20040121
WO 2004-EP4363	W	20040424

OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h